Clik here to view.
FDA approves nonstimulant Shire ADHD drug
Shire-ADHD.jpgFDA, the Food and Drug Administration has given its approval to Shire for the marketing of the drug, Intuniv, which is a nonstimulant treatment for attention-deficit hyperactivity...
View ArticleClik here to view.
FDA Trouble for Shire
Shire.jpgShire has been in trouble after marketers used a small promotional magnet. This magnet was used by the company to promote its new attention-deficit hyperactivity disorder drug Vyvanse. This...
View ArticleClik here to view.
FDA Approves Firazyr to Treat Hereditary Angioedema Patients in US
Firazyr.jpgFood and Drug Administration of US has approved Firazyr to treat hereditary Angioedema patients. HAP is a swelling in subcutaneous tissues.The treatment was approved in Europe in 2008, and...
View ArticleClik here to view.
One more record for Shire
Shire02202.jpegThe pharmaceuticals giant Shire has yet again achieved laurels with its increased share prices reaching another high.read more
View ArticleClik here to view.
Shire Gets Ready To Accept New Offer From AbbVie
Shire.jpgShire, the Dublin based drug manufacturer says that it is ready to urge a fresh £31bn takeover offer that came from AbbVie. It is entering into discussions with the firm after it received its...
View ArticleClik here to view.
Dublin-based Shire’s Internal Synergy Goals from Baxalta Deal are Higher than...
Shire-Plc.jpgFor more than six months Shire had been trying to win over Baxalta, its fellow drug maker. Finally on Monday a deal was agreed upon for a value of approximately $31 billion. The merger...
View Article
